Themutual meeting of LUMIER PHARMA LLC and F.Hoffmann-La Roche Ltd with the representatives of the All-Communities Advisory Council on Access to Treatment in Ukraine (UCAB )

On March 14, 2012, the mutual meeting of LUMIER PHARMA LLC and F.Hoffmann-La Roche Ltd representatives with the representatives of the All-Communities Advisory Council on Access to Treatment in Ukraine (UCAB) was held. The main objective of the meeting was to introduce to the meeting participants the medicine PEGFERON, PEG-interferon alpha 2, manufactured by LUMIER PHARMA LLC and the F.Hoffmann-La Roche Ltd Company; the medication is the first local pegylated interferon designated for the treatment of patients with viral hepatitis and HIV/AIDS with co-infection that demonstrates effectiveness clinically proven both in Ukraine and abroad.